Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 18;191(4):631-633.
doi: 10.1093/bjd/ljae216.

Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life

Daniel Lyons  1 , Anusha Louly Nathan  1 , Emily Pender  1 , Gregg Murray  1 , Conor Smith  2   3 , Brian Kirby  1   2 , Rosalind Hughes  1   2
Affiliations

Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life

Daniel Lyons et al. Br J Dermatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest E.P. has acted as a subinvestigator in clinical trials for AbbVie, MoonLake and UCB. R.H. has been a ­consultant for AbbVie. B.K. has received research support from/was a principal investigator (clinical trials) for AbbVie, Almirall, Janssen, MSD, MoonLake, Novartis, Pfizer and UCB; has been a consultant for AbbVie, Almirall, Amgen, AstraZeneca, Celgene, Janssen, MC2 Therapeutics, MSD, MoonLake, Novartis, Pfizer and UCB; has received honoraria from AbbVie, Amgen, Almirall, Celgene, Janssen, LEO Pharma, Lilly, MC2 Therapeutics, MoonLake, Novartis, Pfizer, UCB and Union; and has been on scientific advisory boards for AbbVie, Almirall, Celgene, Janssen, Lilly, MoonLake, Novartis, Pfizer and UCB. The remaining authors have no conflicts of interest to declare.